Showing results (481-490 of 527) with videos related to
Sort By:
Pageof 53
Gut and Liver|May 31, 2021
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III TrialsJeong Heo, Yoon Jun Kim, Jin-Woo Lee, et al.Journal of Korean Medical Science|August 30, 2008
Clinical features and treatment outcomes of upper gastrointestinal bleeding in patients with cirrhosisYeon Seok Seo, Youn Ho Kim, Sang Hoon Ahn, et al.The Lancet. Oncology|September 13, 2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, et al.Gut and Liver|June 27, 2017
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and ValidationHye Won Lee, Hyun Soo Kim, Seung Up Kim, et al.Liver International : Official Journal of the International Association for the Study of the Liver|November 21, 2013
Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert PanelAnn Lii Cheng, Deepak Amarapurkar, Yee Chao, et al.Nature Communications|November 18, 2018
Serotonin signals through a gut-liver axis to regulate hepatic steatosisWonsuk Choi, Jun Namkung, Inseon Hwang, et al.Journal of Hepatology|May 12, 2019
Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cellsAlexander König, Jaewon Yang, Eunji Jo, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 29, 2020
Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter StudySeung Up Kim, Yeon Seok Seo, Han Ah Lee, et al.Lancet (London, England)|February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 22, 2013
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)Joong-Won Park, Deepak Amarapurkar, Yee Chao, et al.Pageof 53